Automated nitrogen analysis reduces costs per sample

N-Realizer analytical system from C. Gerhardt increases productivity with valve block from Festo

Aurevia

“A major energy boost for the entire cancer vaccine field”

The development of cancer vaccines has accelerated in recent years. Norwegian Ultimovacs is one of the companies attempting to develop a new type of treatment l...

Compact and leak-tight powerhouse

Media-separated solenoid valve VYKA from Festo is virtually leak-free

22 miljarder – så mycket kostar det att utveckla ett nytt läkemedel

Den genomsnittliga kostnaden för Big Pharma att ta ett läkemedel hela vägen från upptäckt till lansering var i fjol 2,23 miljarder dollar, motsvarande en bra bi...

Ny bok om strålbehandling – "Det är en enorm utveckling som skett"

Ungefär hälften av alla som drabbas av cancer får någon gång strålbehandling. Enligt Jan Degerfält, författare till två fackböcker på ämnet, är det få områden s...

Novokonkurrenten Viking faller på nya fetmadata

Viking Therapeutics redovisar en viktminskning på upp till drygt 12 procent för sitt antifetmapiller under utveckling. Men marknaden hade väntat sig mer, och ak...

Founder of Bioarctic, Lars Lannfelt, is honoured: “I want to create something for the future”

It´s like a scientist’s dream: to be the world’s first with a drug that genuinely affects one of our major diseases. Lars Lannfelt and his company Bioarctic hav...

SMC Corporation Appoints Bianca Brunell as New General Manager for the Nordic and Baltic Countries

SMC Corporation is pleased to announce the appointment of Bianca Brunell as the new General Manager for SMC’s Nordic and Baltic countries, effective June 1, 2024.

The Swedish Research Council gets go-ahead for more long-term funding

Following a government decision, the Swedish Research Council will soon be able to approve ten-year grant periods for funding research infrastructure, which may...

Superconductor technology: Contactless working in the laboratory of the future

Automated filling and weighing of freeze-dry containers in the cleanroom with SupraMotion from Festo

TECHNIA AB

Sobi announces agreement with Enable Injections

Swedish biopharma Sobi has entered into an international development and distribution agreement with US drug delivery company Enable Injections.

A+ Science AB

Bygger ett ekosystem för ATMP

Avancerade terapiläkemedel var på agendan vid det vetenskapliga mötet Bioscience i Stockholm under onsdagen. Anna Falk, professor vid Lunds universitet, som tal...

Norwegian cancer research companies merge

The Norwegian companies Ultimovacs and Zelluna Immunotherapy plan to merge. At the same time, it is made clear that Ultimovacs' CEO is leaving the company.

Nocebo – the evil twin that makes you feel worse

The placebo effect is well known in healthcare, but not so its opposite: nocebo. “The effect is small, but it can have major repercussions,” says Uppsala resear...

Hon blir föreståndare för ATMP-center i Lund

Professorn Anna Falk blir föreståndare för Lunds ATMP-center som inrättades tidigare i år.

SupraCube - In life Science

Superconductors must be permanently kept below their transition temperature for levitation. Because of the integrated cooler, applications with superconductors ...

Sofia Wallström is Lif's new CEO

Sofia Wallström has been appointed as the new CEO of the industry organization Lif, the trade association for the research-based pharmaceutical industry in Sweden.

Here are the pharmaceutical companies best prepared for AI

How well prepared are pharmaceutical companies in the field of artificial intelligence? That is what a new analysis has tried to evaluate.

Grönt ljus i EU för läkemedel som ska skydda mot hiv

En ny injektionsbehandling, lenacapavir, som ska ge skydd mot hiv-infektion rekommenderas för godkännande av den europeiska läkemedelsmyndigheten EMA.

The life science strategy – what the industry wants

The process of updating the national life science strategy has begun at the government’s life science office. According to industry stakeholders, Sweden’s compe...

MSD discontinues two Keytruda trials

MSD has stopped two late-stage trials that tested its blockbuster immunotherapy Keytruda as a treatment for skin and lung cancer.